THE prevalence of gonococci possessing partial resistance to penicillin and other antibiotics varies in both time and locality, but for the most part it has continued to increase over the years, and there are now some parts of the world in which the limits of 'single-session' penicillin therapy have been reached because of the unacceptable bulk of the injection (WHO, 1969) . There is a pressing need for regular scrutiny of trends of antibiotic sensitivity and for examination of new antibiotics. Fortunately the rate of discovery of agents effective in the treatment of gonorrhoea is keeping pace with the deteriorating position, but there must be no complacent assumption that such will continue to be the case . A new semi-synthetic antibiotic, rifampicin, is the subject of this report.
Rifampicin (Rimactane) is one of the group of rifamycins produced by Streptomyces mediterranei which has been shown to be active in vivo and in vitro against many Gram-positive and Gram-negative organisms and also, as was the case with the earlier discovered Rifamycin SV, against Mycobacterium tuberculosis.
Rifamycin acts by inhibiting bacterial RNA synthesis of the DNA templates, i.e. it stops the expression of genes (Nature (Lond.), 1969). Such synthesis is achieved by the DNA-dependent enzyme RNA synthetase with which rifampicin interacts, but the antibiotic has no effect on human RNA synthetase and therefore on the synthesis of RNA in mammalian cells (Wehrli, Nuesch, Knusel, and Staehelin, 1968; Umezawa, Mizuno, Yamazaki, and Nitta, 1968) . Anti-bacterial effect has been demonstrated both in vivo (Frontali, Leoni, and Tecce, 1964) and in vitro (Hartmann, Honikel, Kniisel, and Nuesch, 1967) . More recently the antibiotic has been shown in vitro to stop vaccinia virus from multiplying without killing the host cell (Heller, Argaman, Levy, and Goldblum, 1969) . Fuga, 1968; Willcox, Morrison, and Cobbold, 1968) show the drug to be active and, apart from its property of making the urine orange-red, to be free of side-effects in the doses used. Moreover, preliminary findings suggest that, when the drug is used in cases of gonorrohoea, it has no prejudicial effect on the results of dark-field examinations in patients also infected with early syphilis (Fuga, 1968) . Serum concentrations after a single oral dose of 900 mg. have been shown to be as high as 27-2 ,ug./ml. at 2 hrs, 15-44 at 8 hrs, and 8-33 at 12 hrs; even the level of 1-64 ,ug./ml. noted at 24 hrs is in excess of the minimum inhibitory concentration in vitro for the gonococcus (Le Petit Pharmaceuticals, 1968 By no means all patients attended at the times requested. The follow-up and results obtained are shown in Table I .
Thus, of 103 male patients treated, 89 were followedup and there were ten suspected failures (11 2 
Summary and conclusions
The need for the development of new antibiotics for the treatment of gonorrhoea is stressed and the use of a new rifamycin derivative, rifampicin (Rimactane), is described.
Of 103 male patients with acute uncomplicated gonorrhoea treated with single oral doses of 900 mg. of this antibiotic, 89 were followed. There were ten apparent failures (11-2 per cent. of those followed) in patients who denied further exposure to risk of infection. This rate is identical with that of all recurrences within the first 2 weeks after treatment regardless of the possibility of re-infection.
The drug was well tolerated and the results obtained were comparable with those currently being obtained with 1 2 mega units aqueous procaine penicillin. Rifampicin thus provides an alternative means of therapy retaining all the administrative and epidemiological advantages of single-session therapy.
Our thanks are due to Ciba Laboratories and Le Petit Laboratories for supplies of Rifampicin used in this study. 
